TY - JOUR
T1 - Immune responses in COVID-19 and tuberculosis coinfection
T2 - A scoping review
AU - Flores-Lovon, Kevin
AU - Ortiz-Saavedra, Brando
AU - Cueva-Chicaña, Luis A.
AU - Aperrigue-Lira, Shalom
AU - Montes-Madariaga, Elizbet S.
AU - Soriano-Moreno, David R.
AU - Bell, Brett
AU - Macedo, Rodney
N1 - Funding Information:
This work is supported by the US National Institute of Health (NIH) grant R01CA257509 (to BB and RM).
Publisher Copyright:
Copyright © 2022 Flores-Lovon, Ortiz-Saavedra, Cueva-Chicaña, Aperrigue-Lira, Montes-Madariaga, Soriano-Moreno, Bell and Macedo.
PY - 2022/8/26
Y1 - 2022/8/26
N2 - Background and aim: Patients with COVID-19 and tuberculosis coinfection are at an increased risk of severe disease and death. We therefore sought to evaluate the current evidence which assessed the immune response in COVID-19 and tuberculosis coinfection Methods: We searched Pubmed/MEDLINE, EMBASE, Scopus, and Web of Science to identify articles published between 2020 and 2021. We included observational studies evaluating the immune response in patients with tuberculosis and COVID-19 compared to patients with COVID-19 alone. Results: Four cross-sectional studies (372 participants) were identified. In patients with asymptomatic COVID-19 and latent tuberculosis (LTBI), increased cytokines, chemokines, growth factors and humoral responses were found. In addition, patients with symptomatic COVID-19 and LTBI had higher leukocytes counts and less inflammation. Regarding patients with COVID-19 and active tuberculosis (aTB), they exhibited decreased total lymphocyte counts, CD4 T cells specific against SARS-CoV-2 and responsiveness to SARS-CoV-2 antigens compared to patients with only COVID-19. Conclusion: Although the evidence is limited, an apparent positive immunomodulation is observed in patients with COVID-19 and LTBI. On the other hand, patients with COVID-19 and aTB present a dysregulated immune response. Longitudinal studies are needed to confirm these findings and expand knowledge.
AB - Background and aim: Patients with COVID-19 and tuberculosis coinfection are at an increased risk of severe disease and death. We therefore sought to evaluate the current evidence which assessed the immune response in COVID-19 and tuberculosis coinfection Methods: We searched Pubmed/MEDLINE, EMBASE, Scopus, and Web of Science to identify articles published between 2020 and 2021. We included observational studies evaluating the immune response in patients with tuberculosis and COVID-19 compared to patients with COVID-19 alone. Results: Four cross-sectional studies (372 participants) were identified. In patients with asymptomatic COVID-19 and latent tuberculosis (LTBI), increased cytokines, chemokines, growth factors and humoral responses were found. In addition, patients with symptomatic COVID-19 and LTBI had higher leukocytes counts and less inflammation. Regarding patients with COVID-19 and active tuberculosis (aTB), they exhibited decreased total lymphocyte counts, CD4 T cells specific against SARS-CoV-2 and responsiveness to SARS-CoV-2 antigens compared to patients with only COVID-19. Conclusion: Although the evidence is limited, an apparent positive immunomodulation is observed in patients with COVID-19 and LTBI. On the other hand, patients with COVID-19 and aTB present a dysregulated immune response. Longitudinal studies are needed to confirm these findings and expand knowledge.
KW - COVID-19
KW - Mycobacterium tuberculosis
KW - SARS-CoV-2
KW - coinfection
KW - immunity
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85138122022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138122022&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.992743
DO - 10.3389/fimmu.2022.992743
M3 - Review article
AN - SCOPUS:85138122022
SN - 1664-3224
VL - 13
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 992743
ER -
